Analysis on the metabolite composition of serum samples from patients with papillary thyroid carcinoma using nuclear magnetic resonance
- 1 January 2015
- journal article
- research article
- Vol. 8 (10) , 18013-18022
Abstract
Objective: Analysis of the metabolic differences among the papillary thyroid carcinoma (group T) patients, benign thyroid tumor patients (group B) and healthy controls (group H) by nuclear magnetic resonance hydrogen spectrum. Methods: collect twenty serum specimens each from group T, group B and group H. Collect image archive. Use Topspin software, AMIX software and SIMCA-P+ software to calibrate, integrate with PCA and PLS-DA, research the three groups' serum for endogenous metabolic differences. Results: The data of group T and group H established a discrimination model, and the model is correct (P<0.05). The content of metabolites in the serum of team T increased including valine, leucine, isoleucine, lactic acid, alanine, glutamic acid, lysine, glycine, while the lipids, choline, tyrosine decreased. The data of group B and group H established a discrimination model and the model is correct (P<0.05). The content of metabolites in the serum of team B increased including Trimethyl glycine, tyrosine, phenylalanine, valine, leucine, isoleucine, lactic acid, alanine, glutamic acid, while the Lipids and lysine reduced. Conclusion: Compared with team H, there is an obvious metabolic difference in team T and team B. It not only involves glucose metabolism but also the metabolism of lipids, amino acids and nucleic acid.Keywords
This publication has 26 references indexed in Scilit:
- Systems biology approach to stage-wise characterization of epigenetic genes in lung adenocarcinomaBMC Systems Biology, 2013
- Cancer statistics, 2013CA: A Cancer Journal for Clinicians, 2013
- Ultrasound guided fine-needle aspiration biopsy of thyroid nodules: Guidelines and recommendations vs clinical practice; a 12-month study of 89 patientsJournal of Ultrasound, 2012
- Epigenetics Modifications and Therapeutic Prospects in Human Thyroid CancerFrontiers in Endocrinology, 2012
- Cross-Regulation between Oncogenic BRAFV600E Kinase and the MST1 Pathway in Papillary Thyroid CarcinomaPLOS ONE, 2011
- Mutant Metabolic Enzymes Are at the Origin of GliomasCancer Research, 2009
- Detection of Bladder Cancer in Human Urine by Metabolomic Profiling Using High Performance Liquid Chromatography/Mass SpectrometryJournal of Urology, 2008
- Alterations in the tissue inhibitor of metalloproteinase-3 (TIMP-3) are found frequently in human colorectal tumours displaying either microsatellite stability (MSS) or instability (MSI)Cancer Letters, 2005
- Tissue inhibitor of metalloproteinase‐3 (TIMP‐3) gene is methylated in the development of esophageal adenocarcinoma: Loss of expression correlates with poor prognosisInternational Journal of Cancer, 2005
- Early Occurrence of RASSF1A Hypermethylation and Its Mutual Exclusion with BRAF Mutation in Thyroid TumorigenesisCancer Research, 2004